Wilson disease is an autosomal recessive genetic disorder caused by loss-of-function mutations in the P-type copper ATPase, ATP7B, which leads to toxic accumulation of copper mainly in the liver and brain. Wilson disease is treatable, primarily by copper-chelation therapy, which promotes copper excretion. Although several de-coppering drugs are currently available, their Cu(I)-binding affinities have not been quantitatively characterized. Here we determined the Cu(I)-binding affinities of five major de-coppering drugs -D-penicillamine, trientine, 2,3-dimercapto-1-propanol, meso-2,3-dimercaptosuccinate and tetrathiomolybdate -by exploring their ability to extract Cu(I) ions from two Cu(I)-binding proteins, the copper chaperone for cytochrome c oxidase, Cox17, and metallothionein. We report that the Cu(I)-binding affinity of these drugs varies by four orders of magnitude and correlates positively with the number of sulfur atoms in the drug molecule and negatively with the number of atoms separating two SH groups. Based on the analysis of structure-activity relationship and determined Cu(I)-binding affinity, we hypothesize that the endogenous biologically active substance, α-lipoic acid, may be suitable for the treatment of Wilson disease. Our hypothesis is supported by cell culture experiments where α-lipoic acid protected hepatic cells from copper toxicity. These results provide a basis for elaboration of new generation drugs that may provide better therapeutic outcomes.
rapidly, resulting in improvements in copper control and this is accompanied by improved neurologic outcomes and stabilization of liver function, with a favorable safety profile 17 .
De-coppering drugs should compete for copper ions with cellular Cu(I)-binding proteins, for which the Cu(I)-binding affinities are known 18 . However, the Cu(I)-binding affinities of de-coppering drugs, which are of fundamental importance for understanding their therapeutic action, are currently not known. In the current study, Cu(I)-binding affinities of de-coppering drugs were determined from their competition with two cellular Cu(I)-binding proteins, Cox17 and metallothionein (MT), which have different Cu(I)-binding affinities 18 . These proteins were reconstituted to form Cu 1 Cox17 and Cu 10 MT metalloforms and incubated with increasing concentrations of the de-coppering drugs. Demetallation of the copper proteins was monitored by electrospray ionization mass spectrometry (ESI MS) 18 and the copper-binding affinities were determined from dose-dependent demetallation curves. The absolute values for dissociation constants (K d ) of Cu(I)-drug complexes were obtained by comparing demetallation potencies of de-coppering drugs with those of copper chelators with known copper-binding affinities such as dithiotreitol (DTT) and diethyl dithiocarbamate (DETC). Analysis of structure-activity relationships suggested that an endogenous biologically active substance, α-lipoic acid (LA), may serve as a potential de-coppering drug. LA was able to protect hepatic cells from copper toxicity in vitro, which further supports its potential as an anti-copper agent.
Methods
Reagents. Chemical reagents: PA, TR, BAL, DMS, LA, ammonium TTM, diethylammonium DETC were purchased from Sigma-Aldrich, DTT (ultrapure) from USB Corporation, DLA from Santa Cruz Biotechnology. Bischoline TTM (WTX101) was provided by Wilson Therapeutics AB. Rabbit apo-MT2A was purchased from Bestenbalt LLC and apo-Cox17 3S-S was produced as described previously 19 . Recombinant human Cu,Zn-SOD was purchased from Biovision Inc. All solutions were prepared immediately before the experiments in 20 mM ammonium acetate, pH 7.3 buffer in the absence of organic solvents. To avoid oxidation of DTT and proteins, the buffer was saturated with argon. 
Reconstitution of proteins with Cu(I) ions.

ESI-MS settings and determination of copper-binding affinities. DTT is suitable for applications in
ESI MS as being a nonionic compound it does not suppress the ionization efficiency of proteins during ESI-MS substantially, which enables detection of protein peaks even if ligand is present in millimolar concentrations. The Cu(I)-binding affinity of DDT has been studied extensively 18, 20 , and was therefore used as a standard for determination of Cu(I)-binding affinities of DETC, PA, TR, TTM, BAL and DMS. It should be mentioned that DTT is air sensitive and its Cu(I)-binding affinity depends on pH of solution 20 . Therefore all experiments with DTT have been conducted in oxygen-free argon-saturated solutions at pH = 7.3, where the Cu(I)-binding affinity has reliably been determined (K d = 5.01 × 10 −16 M) 20 . Since DETC, PA, TR TTM and DMS are ionic compounds, they lead to ionic suppression of protein peaks in ESI MS spectra. However, ionic suppression is low at submillimolar concentrations and presumably similar for all protein peaks. In a standard experiment, the reconstituted protein was incubated with increasing concentrations of copper chelators for 1 min and samples were injected into the electrospray ion source of an Agilent Technology 6540 UHD Accurate-Mass Q-TOF MS instrument (Agilent) by a syringe pump at 7 μL/min. ESI-MS spectra were recorded for 10 min in the m/z region from 100 to 3,000 Da using the following instrument parameters: capillary voltage = 3500 V, drying gas = 4 l/min, drying gas temperature 100 °C, nebulizer 15 psig, skimmer voltage = 65 V. ESI MS spectral composition was stabilized after 5 min of monitoring time and spectra between 8-10 min were averaged for further analysis. Obtained ESI MS spectra were deconvoluted using the Mass Hunter software (Agilent). The fractional content of metallated protein forms was calculated from the integrated peak areas for metallated and nonmetallated protein forms. C 50 values for compounds have been calculated by fitting the dose-dependent demetallation curve to the simple 1:1 binding isotherm (in case of Cu 1 Cox17) or Hill equation (in case of Cu 10 MT). K d values for the Cu(I)-protein complexes at pH 7.3, 20 mM ammonium acetate, and 25 °C were determined using previously determined K d values for protein-Cu(I) complexes 18 and the re-estimated apparent K d for the Cu(I)-DTT complex of 5.01 × 10 −16 M 20 . K d values for PA, TR, BAL, DMS and TTM, were determined by the ability of these ligands to extract Cu(I) ions from Cu 1 Cox17 or Cu 10 MT in comparison with DTT (in case of Cu 1 Cox17) or DETC (in case of Cu 10 MT) respectively as described above.
Demetallation of Cu,Zn-SOD with TTM. Commercial lyophilized Cu,Zn-SOD was dissolved in
argon-saturated 20 mM ammonium acetate pH 7.3 to the final concentration of 5 µM, and injected at different time points into an Agilent Technology 6540 UHD Accurate-Mass Q-TOF MS instrument by a syringe pump at 7 μL/min. ESI-MS spectra were recorded for 10 min in the m/z region from 500 to 3,000 Da using the instrument parameters presented above. ESI MS spectrum of the sample exposed two peaks: Cu,Zn-SOD and partially demetallated Zn-SOD ( Fig. S9A ). Following incubation of the sample with 10 µM ammonium TTM, there was a time-dependent shift in intensities of the peaks, whereas peak of Cu,Zn-SOD disappeared and peak of apo-SOD appeared in the spectrum (Fig. S9A ). Spectral changes could be interpreted with extraction of Cu(I) and Zn(II) ions from Cu,Zn-SOD and Zn-SOD and formation of Cu-SOD and apo-SOD. The demetallation process occurred with a half-life of 23 ± 14 min ( Fig. S9B ). Cell viability measured by WST-1. The effects of CuCl 2 on the cells were determined using the cell viability assay WST-1 (Roche). WST-1 assay allows colorimetric measurement of cell viability due to reduction of tetrazolium salts to water-soluble formazan by viable cells. 105 cells were seeded in triplicates in a 96 well plate and cultivated for 24 h. Various concentration (0-100 µM) of CuCl 2 were added and the measurements were performed 24 hours after cells treatment. The experiments with no CuCl 2 added were used as a negative control. 5 µl/ well of WST-1 reagent was added to 100 µl of cell culture medium, incubated at 37 °C for 2 h and absorbance was measured at 450 nm using TECAN Genios Pro microplate reader. For LA testing, cells in triplicates were preincubated with various concentrations (0-100 µM) of LA (dissolved in ethanol) for 24 h and medium was changed to fresh medium, containing 50 µM of CuCl 2 and various concentrations (0-100 µM) of LA. Cell viability was determined after 24 h incubation with WST-1 test. Experiments were performed twice.
Results and Discussion
Demetallation of Cu 1 Cox17 by the de-coppering drugs. All de-coppering drugs were able to demetallate Cu 1 Cox17; however, it occurred at different concentrations with different drugs. Demetallation potency of compounds was defined as the concentration where 50% of Cu 1 Cox17 was demetallated and was denoted as C 50 . PA and TR extracted Cu(I) from Cu 1 Cox17 at millimolar concentrations with the corresponding C 50 (PA) = 1.47 mM (Figs 1A and S1) and C 50 (TR) = 1.08 mM (Figs 1B and S1). BAL extracted Cu(I) from Cu 1 Cox17 at micromolar concentrations with C 50 (BAL) = 9.38 μM ( Figs 1C and S3 ). DMS and TTM showed very low C 50 values: C 50 (DMS) = 3.14 μM (Figs 1E and S4 ) and the C 50 (TTM) was less than 1 μM (Figs 1F and S5 ). C 50 values were determined also for reference compounds, DTT (C 50 [DTT] = 3.10 mM) ( Fig. S6) and DETC (C 50 [DETC] = 5.28 μM) ( Fig. S7 ). Based on the linear relationship between C 50 and K d values and the known K d value for DTT 20 , we calculated the K d values for studied compounds and the results are presented in Table 1 . As an example we present here the mathematics for calculation of K d value for DETC. DETC was 587 times more effective Cu(I) chelator than DTT (C 50 [DTT] / C 50 [DETC] = 587), which is in line with earlier results obtained with a different ESI-MS setup 18 . Consequently the K d for Cu(I)-DETC complex should also be 587 times lower as that for DTT and therefore K d (DETC) = 5.01 × 10 −16 / 587 = 8.53 × 10 −19 M.
Demetallation of Cu 10 MT by the de-coppering drugs. In the second series of experiments, we explored the ability of different de-coppering drugs to extract copper from Cu 10 MT, which has 42 times higher Cu(I)-binding affinity as compared to Cu 1 Cox17 18 . TTM demetallated Cu 10 MT at micromolar concentrations through a stepwise process. First, a complex Cu 10 MT-TTM was formed with 1:1 stoichiometry ( Fig. 2A ). Multiple peaks appeared at higher concentrations of TTM, indicative of the binding of a second, third and fourth TTM molecule to the complex and the simultaneous build-up of apo-MT ( Fig. 2A) . The binding of multiple TTM ions appeared to lead to the opening of Cu(I)-thiolate clusters and dissociation of Cu(I) ions from the protein. As dissociation of Cu(I)-thiolate clusters of Cu 10 MT occurred cooperatively we did not observe hyperbolic demetallation curves like in case of Cu 1 Cox17. By this reason fitting of the Cu 10 MT demetallation curves by the influence of TTM was performed by using the Hill equation 18 . A C 50 (TTM) value of 21.1 μM was obtained by taking into account all CuMT-TTM complexes (Fig. 2B ). Both salts of TTM, ammonium and bis-choline TTM, behaved similarly in ESI-MS experiments. Earlier HPLC/ICP experiments have also demonstrated the binding of TTM to CuMT 21 ; however, the exact composition of ternary complexes remained unclear.
DETC also extracted Cu(I) from Cu 10 MT (Fig. 2C) at millimolar concentrations and the corresponding C 50 (DETC) was equal to 0.77 mM (Fig. 2D ). Other de-coppering drugs were unable to demetallate Cu 10 MT up to millimolar concentrations. Based on the linear relationship between C 50 and K d values and the known K d value for DETC (see Table 1 ), the K d value for TTM was calculated (K d = 2.32 × 10 −20 M) and inserted into Table 1 . The absolute value of K d for Cu 10 MT of 4.1 × 10 −16 M was first determined in 2010 18 based on the absolute value of available K d for the Cu(I)-DTT complex known at that time. Subsequently, the K d for the Cu(I)-DTT complex has been corrected from 7.94 × 10 −12 M 22 to 5.01 × 10 −16 M (pH 7.3) 20 . Based on the corrected absolute dissociation constant for Cu(I)-DTT complex, the corrected K d for Cu 10 MT was calculated to be 2.59 × 10 −20 M. 
Clinical implications of demetallation by de-coppering drugs. The obtained information can be
applied to the clinical context. For a sustainable treatment effect in Wilson disease, de-coppering drugs must extract copper from intracellular copper stores, which have, however, different Cu(I)-binding affinities. MT has a high affinity for Cu(I) ions and only one de-coppering drug studied, TTM, had the ability to demetallate Cu 10 MT at low micromolar concentrations. For estimation of the physiological concentration of TTM, we used data from oncology patients where TTM 180 mg/day resulted in C max of 5.7 µM 23 . At such concentrations, TTM can partially demetallate CuMT, which most probably forms the basis of its fast and efficient therapeutic action. MT has one of the highest copper-binding affinities among cellular Cu(I) proteins 18 and TTM may therefore extract copper also from several other essential copper proteins. Other cellular copper chaperones and copper transporters have copper-binding affinities similar to that of Cox17 18 and most probably they can also be demetallated by TTM. Intracellular copper enzymes Cu,Zn-SOD (antioxidative defense) and mitochondrial cytochrome c oxidase (mitochondrial electron transfer) have copper-binding affinities comparable to that of MT 18 . However, the dissociation of metal ions from the active sites of these enzymes is very slow 18 , which might protect them from fast demetallation by TTM. It has been shown that TTM does not inhibit mitochondrial cytochrome c oxidase activity in hepatic mitochondrial preparations at concentrations up to 100 µM even after 16-h incubation 24 , strongly suggesting that TTM cannot demetallate cytochrome c oxidase. Nevertheless, in the same study, TTM inhibited Cu,Zn-SOD in a time-dependent manner 24 . Our data confirm that 10 µM TTM can extract copper from 5 µM Cu,Zn-SOD with a half-life of 23 min (Fig. S8) . Thus, treatment with high doses of TTM may demetallate Cu,Zn-SOD, which should be taken into account in refinement of therapeutic doses for TTM. The K d values for PA and TR were 2.38 × 10 −16 M and 1.74 × 10 −16 M, respectively. Therapeutic doses of PA and TR (750-1500 mg/day 17 ) are substantially higher than that for TTM. The current study suggests that PA and TR cannot effectively compete with CuMT at therapeutic concentrations (approximately 50-100 µM); however, they can partially compete with copper chaperones. At therapeutic concentrations, BAL and DMS effectively demetallated copper chaperones and only partially CuMT; however, the action of DMS is restricted mainly to the extracellular space since it is unable to cross biological membranes.
Structure-affinity relationship analysis and identification of new copper-binding drugs. The
Cu(I)-binding affinity of the de-coppering drugs studied varied by four orders of magnitude depending upon the molecular structure of the compounds. One can speculate that the number of sulfur-containing groups in the molecule, which are well adapted for the coordination of Cu(I) ions, is an important determinant of the binding affinity. Indeed, a positive correlation between the Cu(I)-binding affinities and the number of the S-atoms in the molecule (Fig. 3A) was observed: TTM, with four S-atoms, has the highest Cu(I)-binding affinity, and PA with only one S-atom has the lowest affinity. However, the Cu(I)-binding affinity of DTT is considerably different from that of BAL and DMS, although all these compounds carry two SH groups. Thus, not only the number, but also the position of the sulphur-containing groups appears to affect the Cu(I)-binding affinity of compounds. Indeed, the Cu(I)-binding affinity decreased substantially with increasing number of atoms between the sulfhydryl groups: TTM > BAL, DMS > DTT (Fig. 3B ). This structure-affinity relationship explains why TTM has the highest Cu(I) affinity of all de-coppering agents studied and opens new perspectives for the rational design of new copper-binding drugs.
In order to test the validity of this structure-activity relationship and its applicability for design of new copper-binding drugs, we looked for biomolecules with three intercalating atoms between two SH groups and found that dihydrolipoic acid (DLA) fits these criteria. The experimental Cu(I)-binding affinity of DLA was equal to K d = 8.05 × 10 −17 M (Fig. S9, Table 1 ), which fits well the predicted relationship between logK d and the number of atoms between two SH groups, thus confirming the structure-activity relationship. The Cu(I)-binding affinity of DLA was 2 and 3 times higher than that of TR and PA respectively, however, the affinity was not high enough to directly decopper intracellular high-affinity Cu stores like Cu 10 MT when tested experimentally (data not shown).
In vivo, DLA is formed from α-lipoic acid (LA) by reduction in a cellular environment. LA is a well-tolerated food supplement that is able to cross biological membranes. Considering its higher Cu(I)-binding affinity than that of chelators approved for the treatment of Wilson disease (PA, TR), good membrane and blood brain barrier permeability 25 as well as very good tolerability 26 , we suggest that LA might be a suitable de-coppering drug for treatment of Wilson disease. Some exploratory attempts to use LA in Wilson disease have been reported 27, 28 , however, the potency of LA in the treatment of Wilson disease has not been explored in cellular experiments.
Effect of LA on cellular copper toxicity. To further explore the potential of LA as a de-coppering drug we performed preliminary experiments with Huh7 hepatic cell lines to test the putative protective effect of LA against copper toxicity. Similar experimental setup has been used earlier to demonstrate the protective effect of PA on copper toxicity exerted on hepatic cell lines 29, 30 . The results in Fig. 4 demonstrate that copper is toxic to Huh7 cells with LD 50 of approximately 30 μM of CuCl 2 (Fig. 4a ) and LA exerts a clear dose-dependent protective effect on toxicity of 50 μM CuCl 2 (Fig. 4b) . The protective effect on cellular level supports the potential therapeutic role of LA in treatment of Wilson disease, however, the full spectrum of therapeutic activities of LA should be evaluated in further cellular and animal studies.
